Genmab — Juli 2022
-
Kan være rebalancering efter en en god måned i biotek og pharma. Det er jo månedslut i morgen.
-
Genmab samler ny energi omkring 2600. Mon vi får et større tilbagefald inden vi hilser på 3000 igen og skal fejre sommer-høstfest med varm danskvand?
-
Og som Riis siger kan gevinsten meget vel flyttes over i de grønne aktier.
-
Der er vist et gammelt modstandsområde i 2630-2640 i følge BSinvest. Det er blevet testet et par gange med afvisning til
følge. -
Man må også konstatere, at signalet fra Saxo bank i 2661 kom relativt tæt på kurstoppen i 2663
-
USA/lukning: Aktier steg trods hug til Meta - https://www.proinvestor.com/investornyt/857566/usa-lukning-aktier-steg-trods-hug-til-meta-satser-pa-midelre-fed
-
Godmorgen.
-
-
TIVDAK launch progressing well
• Pleased with positive feedback from oncology community
• Well-positioned in 2L/3L setting; area of high unmet need
https://s21.q4cdn.com/327105422/files/doc_financials/2022/q2/revised/SGEN-2Q22-Presentation-28July2022.pdf -
That will be all net sales and no collaboration rev. Wonder when Genmab will book first sale?
-
Could be. I may ask Mr. Winkel at our next QA. The sales force at Genmab is hopefully busy practicing for Epco release. But would be nice to see some numbers to prove they are progressive now and not just pulling their monthly payment
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind